International Federation of pharmaceutical manufacturers and associations has launched a new Fund to Finance the development of antibacterial drugs. The largest pharmaceutical companies in the world have already sent to the Fund of $ 1 billion, according to Reuters.
The development of new antibiotics plays a key role in the fight against antibiotic resistance, however, companies involved in the creation of antibacterial drugs, are often faced with a lack of investment and bankruptcy even in the case of drug registration.
The new Fund will be a temporary solution for the financing of small biotech companies, until you have taken the necessary legislative measures to support such projects.
Funds to support developers of antibiotics sent including MSD, Pfizer, Eli Lilly, Johnson&Johnson, Novartis and GlaxoSmithKline. It is expected that within 10 years thanks to the financial support of the Fund the market will be 2-4 new antibiotic.